Abstract
Because SSRI or SNRI has relatively few side effects, they are widely used for treatment of depression as first line. However some new adverse effects of the treatments have been reported. Among them, activation syndrome, rapid cycling, or mixed phase may be prevented by prudent treatments of antidepressants with assessment of bipolarity. So- called new- type depression includes atypical depression which has been confirmed to have biological basis and to need an adjustment of whole monoamines. New SNRI Duloxetine can adjust whole monoamines in the prefrontal cortex. The safety of new SSRI Escitalopram is expected because of its allosteric effect on serotonin transporter.
